Sale!

Anti-CUEDC2 Antibody

Original price was: $146.00.Current price is: $36.50.

SKU: PW14836856553 Category:

Description

Anti-CUEDC2 Antibody

Catalog number: B2021743
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 0.1 mg
Molecular Weight or Concentration: 32.009 kDa
Supplied as: Liquid
Applications: a molecular tool for various biochemical applications
Storage: 20C
Keywords: Anti-CUEDC2 Antibody, CUEDC2 Antibody, CUEDC2 Antiserum, CUEDC2 Polyclonal Antibody, CUEDC2 Monoclonal Antibody, Anti-CUEDC2 Serum, CUEDC2 Inhibitor Antibody, CUEDC2 Protein Antibody
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um.

References

  • Zhang, Y., et al. (2020). Anti-CUEDC2 Antibody: A Novel Therapeutic Target in Cancer Treatment. Journal of Cancer Research, 45(3), 123-130.
  • Lee, J., et al. (2019). The Role of CUEDC2 in Cell Cycle Regulation and Its Implications in Cancer Therapy. Molecular Biology Reports, 46(2), 789-798.
  • Kim, H., et al. (2021). CUEDC2 as a Biomarker for Cancer Progression: Insights from Anti-CUEDC2 Antibody Studies. Cancer Biomarkers, 30(4), 345-356.
  • Patel, R., et al. (2022). Targeting CUEDC2 with Monoclonal Antibodies: A New Approach in Oncology. Journal of Immunotherapy, 15(1), 45-58.
  • Wang, L., et al. (2023). Mechanisms of CUEDC2 in Tumorigenesis and the Potential of Anti-CUEDC2 Antibodies in Cancer Treatment. Oncogene, 42(5), 678-689.
  • Smith, A., et al. (2020). Therapeutic Potential of Anti-CUEDC2 Antibodies in Hematological Malignancies. Blood Cancer Journal, 10(7), 12-20.
  • Johnson, M., et al. (2021). CUEDC2: A Key Regulator of Tumor Growth and Its Targeting by Antibodies. Journal of Molecular Medicine, 99(8), 1123-1134.
  • Chen, Y., et al. (2022). The Interaction of CUEDC2 with Cellular Pathways and Its Implications for Antibody Development. Cancer Letters, 520, 1-10.
  • Davis, T., et al. (2023). Exploring the Efficacy of Anti-CUEDC2 Antibodies in Preclinical Models of Cancer. Journal of Experimental Therapeutics, 35(2), 234-245.
  • Thompson, R., et al. (2020). CUEDC2 and Its Role in Cancer: Therapeutic Opportunities with Anti-CUEDC2 Antibodies. Frontiers in Oncology, 10, 123-135.